KW
Kwangdong Healthbio Co., Ltd.
086220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7086220001
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청원군 오창읍 양청송대길 39(송대리), 오창읍
- Website:
- http://www.kd-healthbio.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-04 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2025-05-21 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.1 KB | ||
| 2025-03-25 00:00 |
AGM Information
정기주주총회결과
|
Korean | 15.2 KB | ||
| 2025-03-17 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 9.6 KB | ||
| 2025-03-17 00:00 |
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
|
Korean | 436.1 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 114.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 26.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 25.1 KB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 8.4 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 28.6 KB | ||
| 2024-12-11 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.4 KB | ||
| 2024-10-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2024-10-14 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2024-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.3 KB | ||
| 2024-08-19 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.6 KB |
Automate Your Workflow. Get a real-time feed of all Kwangdong Healthbio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Kwangdong Healthbio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kwangdong Healthbio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Produces APIs & hospital drugs for oncology & specialty diseases; offers contract services.
Russian Federation
LIFE
Russian Federation
LIFE
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland
FARN
Finland
FARN
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America
FATE
United States of America
FATE
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America
FENC
United States of America
FENC
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America
FBLG
United States of America
FBLG
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America
FGEN
United States of America
FGEN
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy
FF
Italy
FF
Provides nutritional supplements for sports nutrition, weight management, and general health.
United States of America
FTLF
United States of America
FTLF
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America
FLGC
United States of America
FLGC
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark
FLUO
Denmark
FLUO